Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.67 SGD
Change Today -0.01 / -1.47%
Volume 3.1M
BIG On Other Exchanges
As of 5:04 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

biosensors international gro (BIG) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/3/15 - $0.85
52 Week Low
12/2/14 - $0.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

biosensors international gro (BIG) Related Businessweek News

No Related Businessweek News Found

biosensors international gro (BIG) Details

Biosensors International Group, Ltd., an investment holding company, develops, manufactures, and markets various medical devices for interventional cardiology and critical care procedures in China, Japan, and internationally. The company operates in four segments: Interventional Cardiology, Critical Care, Cardiac Diagnostic, and Licensing Revenue. The Interventional Cardiology segment supplies proprietary drug-eluting stents, coronary bare-metal stents, accompanying stent delivery balloon catheter systems, angioplasty balloons, and catheters under the BioMimics 3D, BioMatrix Flex, BioMatrix Flex BTK, BioMatrix NeoFlex, BioMatrix, Axxess, BioFreedom, Chroma, BioStream, BioPath, Gazelle, Juno, S-Stent, Powerline, Quadrature Link, and MultiPleat brands. The Critical Care segment supplies catheter systems and related accessories that are used in surgeries, and intensive care treatment and monitoring procedures. This segment offers ACCUTRANS, a disposable blood pressure transducer system; BIOTRANS, a re-usable blood pressure transducer; Multi-Lumen central venous catheters for infant and adult patients to administer medication or fluids, obtain blood tests, and directly obtain cardiovascular measurements; Thermodilution and Pulmonary Artery catheters for pulmonary artery monitoring; Bipolar Pacing catheters for temporary transvenous cardiac pacing to support critical procedures in the catherization lab, CCU, and emergency room settings; Embolectomy catheters; and BIOTRAY devices. The Cardiac Diagnostic segment supplies medical imaging and clinical applications. The Licensing Revenue segment engages in the licensing of its proprietary drug-eluting stent technology and intellectual property. The company was founded in 1990 and is headquartered in Singapore.

Founded in 1990

biosensors international gro (BIG) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $921.0K
Founder and Executive Chairman
Total Annual Compensation: $1.2M
Compensation as of Fiscal Year 2015.

biosensors international gro (BIG) Key Developments

Biosensors International Group, Ltd. to Commercialize BMX-J Drug-eluting Stent System in Japan Starting October 2015

Biosensors International Group, Ltd. announced that the company will commercialize its BMX-J drug-eluting stent system in Japan starting 1 October 2015. BMX-J is an OEM version of the Nobori DES, which consists of Biosensors' unique DES that incorporates a biodegradable polymer and the company's proprietary drug, Biolimus A9, which inhibits restenosis, or re-narrowing of the arteries, following stent implantation. The company first announced the Japan regulatory approval of BMX-J in August in 2015.

Biosensors International Group, Ltd. Provides Revenue Guidance for the Fiscal Year 2016

Biosensors International Group, Ltd. provides revenue guidance for the fiscal year 2016. For the year, The company expects to achieve revenue growth in fiscal year 2016 over fiscal year 2015, and this is projected to be largely driven by sales from BioFreedom and the Cardiac Diagnostics segment as well as further expansion in Japan with the introduction of the BMX-J DES.

Biosensors International Group, Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Biosensors International Group, Ltd. announced consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported total revenue of $67,027,000 compared to $80,211,000 a year ago. Profit from operations was $18,282,000 compared to $15,104,000 a year ago. Profit before exceptional and non-operating items was $15,896,000 compared to $13,161,000 a year ago. Profit before tax was $10,509,000 compared to $8,526,000 a year ago. Profit attributable to equity holders of the company was $9,463,000 or 0.56 US cent per basic and diluted share after exceptional items compared to $9,871,000 or 0.58 US cent per basic and diluted share after exceptional items a year ago. As at June 30, 2015, the company’s net assets per share was 61.13 US cent. Net cash generated from operating activities was $17,287,000 compared to $16,555,000 a year ago. Purchase of property, plant and equipment was $463,000 compared to $15,547,000 a year ago. Purchase of intangible assets was $2,624,000 compared to $1,415,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIG:SP $0.67 SGD -0.01

BIG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $16.57 USD -0.50
View Industry Companies

Industry Analysis


Industry Average

Valuation BIG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSENSORS INTERNATIONAL GRO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at